- FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder Psychiatric Times
- US FDA approves at-home use of BioXcel’s agitation drug Reuters
- U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults Yahoo Finance
- Dexmedetomidine Receives FDA Approval for Acute Treatment for Agitation Associated With Schizophrenia Pharmacy Times
- FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy The American Journal of Managed Care
(Feed generated with FetchRSS)
Source Link
